Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia.

abstract：:Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detecti...

journal_title：Leukemia

authors： van der Velden VH,Cazzaniga G,Schrauder A,Hancock J,Bader P,Panzer-Grumayer ER,Flohr T,Sutton R,Cave H,Madsen HO,Cayuela JM,Trka J,Eckert C,Foroni L,Zur Stadt U,Beldjord K,Raff T,van der Schoot CE,van Dongen JJ,Euro

更新日期：2007-04-01 00:00:00

abstract：:T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer characterized by skewed epigenetic patterns, raising the possibility of therapeutically targeting epigenetic factors in this disease. Here we report that among different cancer types, epigenetic factor TET1 is highly expressed in T-ALL a...

journal_title：Leukemia

authors： Bamezai S,Demir D,Pulikkottil AJ,Ciccarone F,Fischbein E,Sinha A,Borga C,Te Kronnie G,Meyer LH,Mohr F,Götze M,Caiafa P,Debatin KM,Döhner K,Döhner H,González-Menéndez I,Quintanilla-Fend L,Herold T,Jeremias I,Feuring-

更新日期：2020-05-15 00:00:00

abstract：:Tumor-infiltrating T-lymphocytes (T-TIL) are putative mediators of tumor containment that exhibit unique specificity for autologous tumor cells. The magnitude of T-TIL response in biopsy specimens from patients with B-cell lymphoma has been suggested as an independent predictor of clinical outcome. Since recognition o...

journal_title：Leukemia

authors： List AF,Spier CM,Miller TP,Grogan TM

更新日期：1993-03-01 00:00:00

abstract：:The majority of neutralizing antibodies of HTLV-I are directed against linear epitopes of the envelope surface glycoprotein (gp46) in the immunodominant region 175-199. Although gp46 presents a remarkable degree of conservation, the substitution of the proline at position 192 by a serine is described for 10 isolates a...

journal_title：Leukemia

authors： Londos-Gagliardi D,Armengaud MH,Freund F,Dalibart R,Moze E,Huet S,Legrand E,Guillemain BJ

更新日期：1997-04-01 00:00:00

abstract：:Hematopoietic stem cells (HSCs) are uniquely capable of self-renewal and provision of all of the mature elements of the blood and immune system throughout the lifetime of an individual. HSC self-renewal is regulated by both intrinsic mechanisms and extrinsic signals mediated via specialized microenvironments or 'niche...

journal_title：Leukemia

authors： Doan PL,Chute JP

更新日期：2012-01-01 00:00:00

abstract：:Recent work suggests that chronic lymphocytic leukemia (B-CLL) expressing unmutated immunoglobulin V genes could correspond to the proliferation of naive B cells whereas those expressing mutated genes, may correspond to the proliferation of post-germinal center B cells. Current data from gene profiling expression have...

journal_title：Leukemia

authors： Oppezzo P,Magnac C,Bianchi S,Vuillier F,Tiscornia A,Dumas G,Payelle-Brogard B,Ajchenbaum-Cymbalista F,Dighiero G,Pritsch O

更新日期：2002-12-01 00:00:00

abstract：:The current study was undertaken to search for differences in the biology of cytogenetic subgroups in patients with de novo acute myeloid leukemia (AML). In addition, factors influencing the metabolism of cytosine arabinoside (araC) as the key agent of antileukemic activity were assessed. Bone marrow aspirates from 91...

journal_title：Leukemia

authors： Jahns-Streubel G,Braess J,Schoch C,Fonatsch C,Haase D,Binder C,Wörmann B,Büchner T,Hiddemann W

更新日期：2001-03-01 00:00:00

abstract：:Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is involved in BCR-independent functions, such as B-cell migration and adhesion. In chronic lymphocytic leukemia (CLL), Syk becomes activated by ex...

journal_title：Leukemia

authors： Hoellenriegel J,Coffey GP,Sinha U,Pandey A,Sivina M,Ferrajoli A,Ravandi F,Wierda WG,O'Brien S,Keating MJ,Burger JA

更新日期：2012-07-01 00:00:00

abstract：:To develop an effective immunotherapy for B-lineage acute lymphoblastic leukemia (ALL), bispecific monoclonal antibodies (bsAb) were raised by cell fusion of two hybridoma cell lines secreting CD3 and CD19 antibodies. The resulting bispecific antibody contains two different specificities within a single antibody molec...

journal_title：Leukemia

authors： Csóka M,Strauss G,Debatin KM,Moldenhauer G

更新日期：1996-11-01 00:00:00

abstract：:Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT's) and clinical activity of the VTD regimen in 85 patients with advanced and refractory myeloma. The starting dose of V was 1.0 mg/m(2) (days 1, 4, 8, 11, every 21 day) with T added f...

journal_title：Leukemia

authors： Pineda-Roman M,Zangari M,van Rhee F,Anaissie E,Szymonifka J,Hoering A,Petty N,Crowley J,Shaughnessy J,Epstein J,Barlogie B

更新日期：2008-07-01 00:00:00

abstract：:ATP-binding-cassette (ABC) transporters are evolutionary extremely well-conserved transmembrane proteins that are highly expressed in hematopoietic stem cells (HSCs). The physiological function in human stem cells is believed to be protection against genetic damage caused by both environmental and naturally occurring ...

journal_title：Leukemia

authors： Raaijmakers MH

更新日期：2007-10-01 00:00:00

abstract：:Although allogeneic bone marrow transplantation has been shown to be a highly effective treatment for acute and chronic leukemia, leukemic relapse remains a significant problem. Leukemic relapse occurs in recipient cells in the majority of cases, but the paucity of donor cell leukemias may reflect the sensitivity of t...

journal_title：Leukemia

authors： Mc Cann SR,Lawler M,Gardiner N,O'Riordan J,Humphries P,De Arce M

更新日期：1994-04-01 00:00:00

abstract：:The concept of arming antibodies with bioactive payloads for a site-specific therapy of cancer has gained considerable interest in recent years. However, a successful antibody-based targeting approach critically relies on the availability of a tumor-associated target that is not only preferentially expressed in the tu...

journal_title：Leukemia

authors： Angenendt L,Reuter S,Kentrup D,Benk AS,Neumann F,Hüve J,Martens AC,Schwöppe C,Kessler T,Schmidt LH,Sauer T,Brand C,Mikesch JH,Lenz G,Mesters RM,Müller-Tidow C,Hartmann W,Wardelmann E,Neri D,Berdel WE,Roesli C,Sc

更新日期：2018-02-01 00:00:00

abstract：:The main reason for the unfavorable clinical outcome of BCR-ABL1-positive acute lymphoblastic leukemia (ALL) is genetic instability. However, how normal B-cell precursors acquire the genetic changes that lead to transformation has not yet been completely defined. We investigated the expression of the activation-induce...

journal_title：Leukemia

authors： Iacobucci I,Lonetti A,Messa F,Ferrari A,Cilloni D,Soverini S,Paoloni F,Arruga F,Ottaviani E,Chiaretti S,Messina M,Vignetti M,Papayannidis C,Vitale A,Pane F,Piccaluga PP,Paolini S,Berton G,Baruzzi A,Saglio G,Baccar

更新日期：2010-01-01 00:00:00

abstract：:Two pediatric cases of acute lymphoblastic leukemia with L1 morphology who also demonstrated immunoglobulin on the leukemic cell surface are presented. The first patient's disease progressed on standard induction therapy, despite the presence of good prognostic features at presentation. The second patient has achieved...

journal_title：Leukemia

authors： Finlay JL,Borcherding W

更新日期：1988-01-01 00:00:00

abstract：:A prospective, randomized double-blind study comparing the effects of irradiated and unirradiated white blood cells was conducted in 108 acute leukemia patients with life-threatening infections, refractory to antibiotics. The study demonstrated no significant improvement in 30-day survival or overall survival. Transfu...

journal_title：Leukemia

authors： Freireich EJ,Lichtiger B,Mattiuzzi G,Martinez F,Reddy V,Kyle Wathen J

更新日期：2013-04-01 00:00:00

abstract：:Forty of the 550 patients (7%) entered to the 11q23 Workshop had secondary (s) acute lymphoblastic leukemia (nine cases), s-acute myeloid leukemia (25 cases, predominantly of FAB type M5), s-acute leukemia unspecified (one case) or s-myelodysplastic syndrome (five cases) following treatment for a primary malignancy. B...

journal_title：Leukemia

authors： Secker-Walker LM,Moorman AV,Bain BJ,Mehta AB

更新日期：1998-05-01 00:00:00

abstract：:Small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitors (CDKIs) are of particular interest due to their potent antitumor activity independent of p53 gene alterations. P53 deletion is associated with a very poor prognosis in multiple myeloma (MM). In this regard, we tested the anti-MM activity of RGB-286...

journal_title：Leukemia

authors： Cirstea D,Hideshima T,Santo L,Eda H,Mishima Y,Nemani N,Hu Y,Mimura N,Cottini F,Gorgun G,Ohguchi H,Suzuki R,Loferer H,Munshi NC,Anderson KC,Raje N

更新日期：2013-12-01 00:00:00

abstract：:Mesenchymal stromal cells (MSCs) are multipotent cells, which exhibit broad immunosuppressive activities. Moreover, they may be administered irrespectively of human leukocyte antigen (HLA) compatibility, without inducing life-threatening immunological reactions, as they express no HLA class II and limited HLA class I ...

journal_title：Leukemia

authors： Balan A,Lucchini G,Schmidt S,Schneider A,Tramsen L,Kuçi S,Meisel R,Bader P,Lehrnbecher T

更新日期：2014-10-01 00:00:00

abstract：:Human DNA ligase was purified from different kinds of immunocompetent cells: thymocytes, normal and stimulated lymphocytes, blasts from ALL (Burkitt and non-T, non-B) and ANLL (M1, M2, and M5). Based upon the protocol for the treatment of these leukemias, the purified enzymes were assayed in the presence of routinely ...

journal_title：Leukemia

authors： Lamballe F,Maniey D,Boscher MY,Fauchet R,le Prise PY,David JC

更新日期：1988-06-01 00:00:00

abstract：:Arsenic trioxide (ATO) induces disease remission in acute promyelocytic leukemia (APL) patients, but not in non-APL acute myeloid leukemia (AML) patients. ATO at therapeutic concentrations (1-2 μM) induces APL NB4, but not non-APL HL-60, cells to undergo apoptosis through the mitochondrial pathway. The role of antiapo...

journal_title：Leukemia

authors： Wang R,Xia L,Gabrilove J,Waxman S,Jing Y

更新日期：2013-02-01 00:00:00

abstract：:We investigated the expression of P-glycoprotein (P-gp) in 52 adults with de novo acute myelogenous leukemia (AML) at the initial diagnosis. We tested 52 patients by flow cytometry using the MRK16 monoclonal antibody (MoAb). To investigate the phenotype for multidrug resistance, 41 of the patients were analyzed using ...

journal_title：Leukemia

authors： Ino T,Miyazaki H,Isogai M,Nomura T,Tsuzuki M,Tsuruo T,Ezaki K,Hirano M

更新日期：1994-09-01 00:00:00

abstract：:To assess the efficacy and toxicity of HAA regimen (homoharritonine 4 mg/m2/day, days 1-3; cytarabine 150 mg/m2/day, days 1-7; aclarubicin 12 mg/m2/day, days 1-7) as an induction therapy in the treatment of de novo acute myeloid leukemia (AML), 48 patients with newly diagnosed AML, aged 35 (14-57) years, were entered ...

journal_title：Leukemia

authors： Jin J,Jiang DZ,Mai WY,Meng HT,Qian WB,Tong HY,Huang J,Mao LP,Tong Y,Wang L,Chen ZM,Xu WL

更新日期：2006-08-01 00:00:00

abstract：:Adult BL/6 mice are highly sensitive to lymphomagnesis by the radiation leukemia virus variant A-RadLV (80-100% T-cell lymphoma incidence after a latency of 70-110 days). This study shows that the in vivo elimination of T-cell subsets (including suppressor and cytotoxic T-cells) achieved by the repeated administration...

journal_title：Leukemia

authors： Haran-Ghera N,Peled A

更新日期：1991-06-01 00:00:00

abstract：:Membrane-derived vesicles (MV) are released from the surface of activated eucaryotic cells and exert pleiotropic effects on surrounding cells. Since the maintenance of pluripotency and undifferentiated propagation of embryonic stem (ES) cells in vitro requires tight cell to cell contacts and effective intercellular si...

journal_title：Leukemia

authors： Ratajczak J,Miekus K,Kucia M,Zhang J,Reca R,Dvorak P,Ratajczak MZ

更新日期：2006-05-01 00:00:00

abstract：:A patient with Philadelphia positive (Ph'+) acute lymphoblastic leukemia (ALL), in remission for over 4 years, developed an acute myeloblastic leukemia (AML), M2-type. During the second disease, the blast cells displayed a typical t(8;21)(q22;q22) translocation, in the absence of the Ph' chromosome. This is the first ...

journal_title：Leukemia

authors： De Cuia MR,Alimena G,Gastaldi R,Spiriti MA,Giona F,Mancini M,Mandelli F

更新日期：1989-04-01 00:00:00

abstract：:Although the prospect of long-term leukemia-free survival (LFS) after treatment for adult acute lymphoblastic leukemia (ALL) is widely accepted, few studies have reported long-term survival data. Three hundred and seventy-eight ALL patients, referred to our hospital from 1978 to 1999, were reviewed for long-term follo...

journal_title：Leukemia

authors： Thomas X,Danaïla C,Le QH,Sebban C,Troncy J,Charrin C,Lhéritier V,Michallet M,Magaud JP,Fiere D

更新日期：2001-12-01 00:00:00

abstract：:Synergistic molecular vulnerabilities enhancing hypomethylating agents in myeloid malignancies have remained elusive. RNA-interference drug modifier screens identified antiapoptotic BCL-2 family members as potent 5-Azacytidine-sensitizing targets. In further dissecting BCL-XL, BCL-2 and MCL-1 contribution to 5-Azacyti...

journal_title：Leukemia

authors： Bogenberger JM,Kornblau SM,Pierceall WE,Lena R,Chow D,Shi CX,Mantei J,Ahmann G,Gonzales IM,Choudhary A,Valdez R,Camoriano J,Fauble V,Tiedemann RE,Qiu YH,Coombes KR,Cardone M,Braggio E,Yin H,Azorsa DO,Mesa RA,Ste

更新日期：2014-08-01 00:00:00

abstract：:Reduced-intensity conditioning (RIC) regimens have been increasingly used as an alternative to conventional myeloablative conditioning (MAC) regimens for elderly patients, for patients medically infirm to qualify for conventional allogeneic stem cell transplantation (SCT), and for disorders in which traditional MAC-SC...

journal_title：Leukemia

authors： Jiménez M,Ercilla G,Martínez C

更新日期：2007-08-01 00:00:00

abstract：:Thirty-two adult patients with acute leukemia were treated with continuous infusion carboplatin and etoposide at eight different dose levels. Dose limiting toxicity was encountered at doses of carboplatin of 310 mg/m2 per day for 5 days (total 1550 mg/m2 per course) and etoposide 150 mg/m2 per day for 5 days (total do...

journal_title：Leukemia

authors： Lee EJ,Reck K,Carter C,Hodges S,Schiffer CA

更新日期：1993-10-01 00:00:00